company background image

Psychemedics NasdaqCM:PMD Stock Report

Last Price


Market Cap







15 Aug, 2022


Company Financials
PMD fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health5/6

PMD Stock Overview

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally.

Psychemedics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Psychemedics
Historical stock prices
Current Share PriceUS$6.49
52 Week HighUS$8.90
52 Week LowUS$6.01
1 Month Change3.34%
3 Month Change0.78%
1 Year Change-5.39%
3 Year Change-10.85%
5 Year Change-66.84%
Change since IPO-39.23%

Recent News & Updates

Aug 09

Psychemedics GAAP EPS of -$0.06, revenue of $6.51M

Psychemedics press release (NASDAQ:PMD): Q2 GAAP EPS of -$0.06. Revenue of $6.51M (+6.9% Y/Y).

Shareholder Returns

PMDUS HealthcareUS Market

Return vs Industry: PMD underperformed the US Healthcare industry which returned 14.7% over the past year.

Return vs Market: PMD exceeded the US Market which returned -10.2% over the past year.

Price Volatility

Is PMD's price volatile compared to industry and market?
PMD volatility
PMD Average Weekly Movement4.1%
Healthcare Industry Average Movement8.7%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: PMD is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: PMD's weekly volatility (4%) has been stable over the past year.

About the Company

1986139Ray Kubacki

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time.

Psychemedics Fundamentals Summary

How do Psychemedics's earnings and revenue compare to its market cap?
PMD fundamental statistics
Market CapUS$37.41m
Earnings (TTM)-US$1.18m
Revenue (TTM)US$26.13m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PMD income statement (TTM)
Cost of RevenueUS$16.16m
Gross ProfitUS$9.97m
Other ExpensesUS$11.16m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.21
Gross Margin38.17%
Net Profit Margin-4.52%
Debt/Equity Ratio7.7%

How did PMD perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio

Does PMD pay a reliable dividends?

See PMD dividend history and benchmarks
When do you need to buy PMD by to receive an upcoming dividend?
Psychemedics dividend dates
Ex Dividend DateAug 23 2022
Dividend Pay DateSep 09 2022
Days until Ex dividend6 days
Days until Dividend pay date23 days

Does PMD pay a reliable dividends?

See PMD dividend history and benchmarks
We’ve recently updated our valuation analysis.


Is PMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PMD?

Other financial metrics that can be useful for relative valuation.

PMD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.5x
Enterprise Value/EBITDA23.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does PMD's PS Ratio compare to its peers?

PMD PS Ratio vs Peers
The above table shows the PS ratio for PMD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.3x
CCEL Cryo-Cell International
VVOS Vivos Therapeutics
CTEK CynergisTek
AIH Aesthetic Medical International Holdings Group
PMD Psychemedics

Price-To-Sales vs Peers: PMD is expensive based on its Price-To-Sales Ratio (1.4x) compared to the peer average (1.3x).

Price to Earnings Ratio vs Industry

How does PMD's PE Ratio compare vs other companies in the US Healthcare Industry?

Price-To-Sales vs Industry: PMD is good value based on its Price-To-Sales Ratio (1.4x) compared to the US Healthcare industry average (1.5x)

Price to Sales Ratio vs Fair Ratio

What is PMD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PMD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PMD's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of PMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PMD ($6.49) is trading above our estimate of fair value ($2.17)

Significantly Below Fair Value: PMD is trading above our estimate of fair value.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Psychemedics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Psychemedics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Examine Psychemedics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.

Past Performance

How has Psychemedics performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PMD is currently unprofitable.

Growing Profit Margin: PMD is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: PMD is unprofitable, and losses have increased over the past 5 years at a rate of 60.6% per year.

Accelerating Growth: Unable to compare PMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PMD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (8.1%).

Return on Equity

High ROE: PMD has a negative Return on Equity (-9.89%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Psychemedics's financial position?

Financial Health Score


Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: PMD's short term assets ($10.9M) exceed its short term liabilities ($5.3M).

Long Term Liabilities: PMD's short term assets ($10.9M) exceed its long term liabilities ($3.2M).

Debt to Equity History and Analysis

Debt Level: PMD has more cash than its total debt.

Reducing Debt: PMD's debt to equity ratio has reduced from 9.8% to 7.7% over the past 5 years.

Debt Coverage: PMD's debt is well covered by operating cash flow (91.8%).

Interest Coverage: Insufficient data to determine if PMD's interest payments on its debt are well covered by EBIT.

Balance Sheet

Discover healthy companies


What is Psychemedics's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Upcoming Dividend Payment

TodayAug 16 2022Ex Dividend DateAug 23 2022Dividend Pay DateSep 09 202217 days from Ex DividendBuy in the next 6 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: PMD's dividend (4.31%) is higher than the bottom 25% of dividend payers in the US market (1.47%).

High Dividend: PMD's dividend (4.31%) is in the top 25% of dividend payers in the US market (3.95%)

Stability and Growth of Payments

Stable Dividend: PMD's dividend payments have been volatile in the past 10 years.

Growing Dividend: PMD's dividend payments have fallen over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: PMD is paying a dividend but the company is unprofitable.

Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (235.5%), PMD's dividend payments are not well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Ray Kubacki (77 yo)





Mr. Raymond C. Kubacki, also known as Ray, has been the President and Chief Executive Officer at Psychemedics Corporation since July 1991. Prior to joining Psychemedics Corporation, Mr. Kubacki served as V...

CEO Compensation Analysis

Compensation vs Market: Ray's total compensation ($USD623.85K) is about average for companies of similar size in the US market ($USD759.98K).

Compensation vs Earnings: Ray's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: PMD's management team is seasoned and experienced (23.6 years average tenure).

Board Members

Experienced Board: PMD's board of directors are seasoned and experienced ( 23.6 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Psychemedics Corporation's employee growth, exchange listings and data sources

Key Information

  • Name: Psychemedics Corporation
  • Ticker: PMD
  • Exchange: NasdaqCM
  • Founded: 1986
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: US$37.414m
  • Shares outstanding: 5.63m
  • Website:

Number of Employees


  • Psychemedics Corporation
  • 289 Great Road
  • Suite 200
  • Acton
  • Massachusetts
  • 1720
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/15 00:00
End of Day Share Price2022/08/15 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.